SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
cas12320-sup-0001-Supporting-information.pdfapplication/PDF544K

Doc. S1. Supporting information regarding molecular docking.

Fig. S1. Effects of imatinib, flumatinib, and sunitinib on the phosphorylation of KIT, ERK1/2, and signal transducer and activator of transcription-3 (STAT3) in 32D-V559D + N822K and 32D-V559D + A829P cells.

Fig. S2. Effects of imatinib, flumatinib, and sunitinib on the body weight of mice after injection of 32D-V559D or 32D-V559D + Y823D cells.

Fig. S3. Effects of imatinib, flumatinib, and sunitinib on the phosphorylation of KIT, ERK1/2, and signal transducer and activator of transcription-3 (STAT3) in 32D-D816H and 32D-N822K cells.

Fig. S4. Plane diagrams showing the interactions between KIT kinase domain and imatinib/flumatinib.

Table S1. Imatinib, flumatinib, sunitinib, nilotinib, dasatinib, sorafenib, and cabozantinib IC50 values of 32D cell lines expressing transforming KIT mutants.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.